Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What percentage of a drug is eliminated after four half-lives in first-order kinetics?

93.75%. ***93.75%*** - In **first-order kinetics**, a constant **fraction** (not amount) of the drug is eliminated per unit time - After 1 half-life: 50% eliminated (50% remains) - After 2 half-lives: 75% eliminated (25% remains) - After 3 half-lives: 87.5% eliminated (12.5% remains) - After 4 half-lives: **93.75% eliminated** (6.25% remains) *84.00%* - This represents approximately 16% remaining drug - Would occur between the 2nd and 3rd half-lives, not at exactly 4 half-lives - Does not correspond to the mathematical progression of first-order kinetics *80.00%* - This represents 20% remaining drug - Does not correspond to any whole number of half-lives - Falls between 2 half-lives (75% eliminated) and 3 half-lives (87.5% eliminated) *5.00%* - This suggests only 5% elimination with 95% drug remaining - Would occur very early in the elimination process, less than 1 half-life - Fundamentally incorrect for 4 half-lives where 93.75% should be eliminated

Q: What is the definition of bioavailability?

Ratio of Area of oral to Area of IV. ***Ratio of Area of oral to Area of IV*** - **Bioavailability (F)** is defined as the **fraction** of an administered dose of unchanged drug that reaches the systemic circulation - It is calculated as: **F = AUC_oral / AUC_IV** (when doses are equal) - This gives a value between **0 and 1** (e.g., F = 0.75 means 75% bioavailable) - This is the **standard pharmacological definition** as per Goodman & Gilman and other authoritative texts *Ratio of Area of oral to Area of IV multiplied by 100* - This expresses bioavailability as a **percentage** rather than a fraction - While bioavailability can be *communicated* as a percentage (e.g., "75% bioavailable"), the formal definition is as a **fraction** - Multiplying by 100 is a conversion for expression, not part of the core definition *Ratio of Area of IV to Area of oral* - This is the **inverse ratio** of bioavailability - It would give values **greater than 1** for drugs with incomplete absorption - Does not represent the fraction of oral dose reaching systemic circulation *Ratio of Area of IV to Area of oral multiplied by 100* - This combines two errors: **inverse ratio** and percentage conversion - Would yield values >100% for drugs with bioavailability <1 - Completely incorrect definition of bioavailability

Q: Which of the following factors does not affect the action of lignocaine?

Action of cholinesterase at the site of injection. ***Action of cholinesterase at the site of injection*** - **Lidocaine** is an **amide-type local anesthetic** and is primarily metabolized by the liver, not by cholinesterases. - Cholinesterases are responsible for metabolizing **ester-type local anesthetics** (e.g., procaine) and acetylcholine. *PH at the site of injection* - The **pH** at the injection site significantly affects lignocaine's action, as its **unionized form** (which is favored in alkaline pH) is essential for penetrating nerve membranes. - In acidic environments (e.g., infected tissue), less unionized lignocaine is available, leading to reduced efficacy. *Blood flow at the site of injection* - **Increased blood flow** at the site of injection can accelerate the systemic absorption of lignocaine, thereby reducing its duration of action at the nerve. - **Decreased blood flow** can prolong its local action, but also increase the risk of systemic toxicity if absorption is very slow. *Vasoconstrictor in the L.A solution* - The addition of a **vasoconstrictor** (e.g., epinephrine) slows the systemic absorption of lignocaine from the injection site. - This **prolongs the duration of action** and reduces the risk of systemic toxicity by keeping the anesthetic concentrated at the target nerves.

Q: Which among the following drugs produces a dose ceiling effect?

Buprenorphine (partial agonist). ***Buprenorphine*** - **Buprenorphine** is a **partial opioid agonist**, meaning its effects, particularly respiratory depression, plateau at higher doses. - This **ceiling effect** means that increasing the dose beyond a certain point does not produce additional analgesic or respiratory depressant effects, making it safer in terms of overdose risk. *Alfentanil (short-acting opioid)* - **Alfentanil** is a **full opioid agonist** that does not exhibit a dose ceiling effect; its effects, including respiratory depression, continue to increase with higher doses. - It is known for its **rapid onset and short duration of action**, making it suitable for brief procedural sedation. *Remifentanil (ultra-short-acting opioid)* - **Remifentanil** is an **ultra-short-acting full opioid agonist** with no dose ceiling effect, meaning its pharmacological effects escalate with increasing doses. - Its unique **esterase metabolism** allows for very rapid offset, making it ideal for maintaining precise anesthetic depth. *Morphine (full agonist)* - **Morphine** is a **full opioid agonist** that does not have a dose ceiling effect; its analgesic and respiratory depressant effects continue to increase as the dose is raised. - It is a **prototypical opioid** often used for moderate to severe pain and is associated with significant dose-dependent side effects.

Q: What is the main barrier for the diffusion of local anesthetic?

Perineurium. **Perineurium** - The **perineurium** is the main barrier to the diffusion of local anesthetics, forming a tight sheath that surrounds fascicles of nerve fibers. - Its **tight junctions** between cells create a blood-nerve barrier, restricting the passage of substances into the nerve. *Epineurium* - The **epineurium** is the outermost connective tissue layer covering the entire nerve, which is relatively loose and offers little resistance to anesthetic diffusion. - Its main function is to provide **protection** and cushioning to the nerve, rather than acting as a diffusion barrier. *Endoneurium* - The **endoneurium** is the delicate connective tissue that surrounds individual nerve fibers within a fascicle. - While it provides structural support, it is **highly permeable** and does not significantly impede the diffusion of local anesthetics. *None of the options.* - This option is incorrect because the **perineurium** is a well-established anatomical barrier for local anesthetic diffusion.

Q: Which of the following drugs is a prodrug that, after oral administration, is converted to an active agent, penciclovir?

Famciclovir. ***Famciclovir*** - **Famciclovir** is an oral prodrug of **penciclovir**. After absorption, it undergoes first-pass metabolism to penciclovir, its active antiviral form. - **Penciclovir** is effective against **herpes simplex virus (HSV)** and **varicella-zoster virus (VZV)**, inhibiting viral DNA polymerase. *Acyclovir (active drug)* - **Acyclovir** is an active antiviral drug and is well-known for its use directly as an antiviral, not as a prodrug for penciclovir. - Although it is also converted to an active triphosphate form inside infected cells, its structure is distinct from penciclovir. *Ganciclovir (for CMV infections)* - **Ganciclovir** is an antiviral drug primarily used to treat and prevent **cytomegalovirus (CMV)** infections. - It is an active nucleoside analog itself, similar to acyclovir, and is not a prodrug for penciclovir. *Fomivirsen (used for CMV retinitis)* - **Fomivirsen** is an antisense oligonucleotide used specifically for the treatment of **CMV retinitis** in AIDS patients. - Its mechanism of action involves binding to CMV mRNA to inhibit viral protein synthesis, and it is unrelated to penciclovir.

Q: Which of the following drugs is least likely to cross the blood-placental barrier?

Glycopyrrolate. ***Glycopyrrolate*** - Glycopyrrolate is a **quaternary ammonium compound**, meaning it is highly ionized and has a low lipid solubility. - Its **polar nature** and **larger molecular weight** restrict its ability to readily cross lipid membranes, including the blood-placental barrier. *Atropine* - **Atropine** is a tertiary amine, making it a **lipid-soluble** compound. - Its lipid solubility allows it to **easily cross the blood-placental barrier** and affect the fetus. *Physostigmine* - Physostigmine is also a **tertiary amine** and is relatively **lipid-soluble**. - This property enables it to **readily cross lipid barriers** such as the blood-placental barrier and the blood-brain barrier. *Hyoscine hydrobromide* - **Hyoscine hydrobromide** (scopolamine) is a **tertiary amine** and highly **lipid-soluble**. - Its high lipid solubility allows for its **easy passage across the blood-placental barrier** and into the fetal circulation.

Q: Which of the following statements about warfarin is false?

Warfarin does not cross the placenta. ***Warfarin does not cross the placenta*** - Warfarin **rapidly crosses the placenta**, leading to fetal exposure and potential teratogenic effects, such as **fetal warfarin syndrome**. - This characteristic makes warfarin generally **contraindicated during pregnancy**, especially in the first trimester. *Half-life is 25 to 60 hours* - The half-life of warfarin is indeed relatively long, ranging from approximately **25 to 60 hours**, which contributes to its once-daily dosing. - This prolonged half-life means that changes in dosing take several days to reach a **new steady-state** and affect the International Normalized Ratio (INR). *Inhibits vitamin K dependent clotting factor synthesis* - Warfarin functions as a **vitamin K antagonist**, inhibiting the hepatic synthesis of vitamin K-dependent clotting factors **II, VII, IX, and X**. - It achieves this by blocking **vitamin K epoxide reductase**, an enzyme essential for reactivating vitamin K. *Contraindicated in patients with severe hepatic failure* - Warfarin is primarily metabolized in the **liver** by cytochrome P450 enzymes, and its clotting factors are synthesized in the liver. - Therefore, **severe hepatic failure** can impair both warfarin metabolism and the production of clotting factors, leading to an increased risk of bleeding and making it a contraindication.

Question 1

What percentage of a drug is eliminated after four half-lives in first-order kinetics?

Accepted Answer

93.75%

Answer

84.00%

Answer

80.00%

Answer

5.00%

Question 2

What is the definition of bioavailability?

Accepted Answer

Ratio of Area of oral to Area of IV

Answer

Ratio of Area of IV to Area of oral

Answer

Ratio of Area of IV to Area of oral multiplied by 100

Answer

Ratio of Area of oral to Area of IV multiplied by 100

Question 3

Which of the following factors does not affect the action of lignocaine?

Accepted Answer

Action of cholinesterase at the site of injection

Answer

PH at the site of injection

Answer

Vasoconstrictor in the L.A solution

Answer

Blood flow at the site of injection

Question 4

Which among the following drugs produces a dose ceiling effect?

Accepted Answer

Buprenorphine (partial agonist)

Answer

Alfentanil (short-acting opioid)

Answer

Remifentanil (ultra-short-acting opioid)

Answer

Morphine (full agonist)

Question 5

What is the mechanism by which standard doses of lidocaine can lead to cardiac or central nervous system toxicity in patients with circulatory failure?

Accepted Answer

Lidocaine concentration can increase in well-perfused tissues such as the brain and heart during circulatory failure.

Answer

Histamine receptors in the brain and heart are activated during circulatory failure.

Answer

There is a sudden release of catecholamines in the brain and heart during circulatory failure.

Answer

Lidocaine is metabolized in the liver, but this does not lead to a toxic metabolite.

Question 6

What is the main barrier for the diffusion of local anesthetic?

Accepted Answer

Perineurium

Answer

Epineurium

Answer

Endoneurium

Answer

None of the options.

Question 7

Which of the following drugs is a prodrug that, after oral administration, is converted to an active agent, penciclovir?

Accepted Answer

Famciclovir

Answer

Acyclovir

Answer

Ganciclovir

Answer

Fomivirsen

Question 8

Which of the following drugs is least likely to cross the blood-placental barrier?

Accepted Answer

Glycopyrrolate

Answer

Atropine

Answer

Physostigmine

Answer

Hyoscine hydrobromide

Question 9

All of the following statements regarding the bioavailability of a drug are true except which one?

Accepted Answer

Low oral availability always and necessarily means poor absorption

Answer

It is a fraction of administered drug that reaches the systemic circulation in unchanged form

Answer

Bioavailability can be determined from plasma concentration or urinary excretion data.

Answer

Bioavailability of an orally administered drug can be calculated by comparing the Area Under Curve after oral and intravenous administration

Question 10

Which of the following statements about warfarin is false?

Accepted Answer

Warfarin does not cross the placenta

Answer

Half-life is 25 to 60 hours

Answer

Inhibits vitamin K dependent clotting factor synthesis

Answer

Contraindicated in patients with severe hepatic failure

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?